Fig. 4: Biological consequences of MPDOLs in vitro.
From: Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
a Diagram illustrating the intracellular fate of MPDOLs and their roles in exosome production in LLC cells. b Flow cytometry analysis and c quantitative analysis of the MFI of C6-labeled MPDOLs internalized by LLC cells (n = 3 independent experiments). d Effect of different endocytosis inhibitors on MPDOL internalization in LLC cells (n = 3 independent experiments). e Confocal microscopy showing lysosomal escape of MPDOLs in LLC cells after 4, 8, and 12 h of incubation, scale bar, 10 μm. f Acridine orange staining of lysosomal damage induced by MPDOLs, scale bar, 40 μm. g qRT-PCR analysis of IGF2BP3 mRNA levels (n = 3 independent experiments) and h western blot analysis of IGF2BP3 protein expression in LLC cells treated with different formulations. i Cell viability of LLC cells treated with free OST, PDs, and MPDOLs at various concentrations for 48 h (n = 4 independent experiments). j The total apoptosis rate of LLC cells after incubation with different preparations for 48 h measured by flow cytometry (n = 3 independent experiments). Data are presented as mean ± SD. Violin plot of d depicting data distribution with the minimum and maximum values, median (center), interquartile range (box bounds), and whiskers extending to 1.5× IQR. g and j were calculated using the one-way ANOVA with a Tukey post hoc test. Source data are provided as a Source Data file.
